SHIPPEO
13.6.2022 10:02:09 CEST | Business Wire | Press release
Shippeo , a leading provider of global and multimodal shipment visibility, has partnered with Everysens , a leader in rail and intermodal transport management systems, to enhance their multimodal transport visibility offering. Everysens will provide Shippeo with the most reliable rail ETA available on the market, based on real-time data from satellite tracking and rail operators.
The two-way partnership allows Everysens to also benefit from Shippeo’s large network of road and ocean carriers, providing high quality shipment tracking data to rail and intermodal shippers and their customers. By sharing container events for ocean shipments, as well as highly accurate and reliable road freight ETAs , Everysens can better anticipate impacts on rail logistics .
In turn, Shippeo receives a stream of rail events from Everysens , including ETAs, GPS positions and loading statuses. Everysens provides ETAs for both full trains and single wagons ; a unique capability within the market. The improved visibility across all types of rail transport will be available globally for Shippeo customers. In addition, Everysens covers the full transport process , including tendering, collaborative smart planning, freight letters and CO2 emissions.
By integrating their respective shipment ETAs, both companies are able to offer their customers improved end-to-end visibility in a single offering, creating new opportunities for supply chain convergence and benefitting shippers with a higher level of supply chain transparency and optimised logistics flows.
“As shippers face more and more supply chain challenges around the world as a result of disruptive global events, they want to know when their shipments will reach their final destination,” explains Lucien Besse, COO and Co-founder at Shippeo. “With sustainability playing an increasingly important role in transportation management, rail is becoming a popular means of intermodal transport. However, visibility over rail shipments has not been easy for shippers to achieve. The partnership between Shippeo and Everysens increases shippers’ trust in rail and multimodal deliveries , providing them with critical monitoring milestones, as well as the ability to measure and improve their processes.”
“Rail is already an important part of multimodal logistics. Effects of the EU Green Deal are quickly positioning rail further as the future of freight,” says Dr. Youness Lemrabet, CEO and Founder of Everysens. “The target is clear: 30% modal share for rail by 2030, with an estimated impact of 290 million tons of CO2 saved . To reach this, rail needs newcomers, for whom intermodal is the primary entry point. With this partnership, we can connect the dots between rail and first- and last-mile transport modes, to make modal shift truly happen .”
About Shippeo
Shippeo
is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more collaborative, automated, sustainable, profitable, and customer-centric supply chains with highly accurate, real-time operational visibility and perfect workflow orchestration. Their Multimodal Visibility Network integrates with more than 875 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and accurately measure CO2 and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries. Learn more at www.shippeo.com
LinkedIn
, Facebook
, Twitter
About Everysens
Decarbonising transport, one train at a time. Everysens offers the first Transport Visibility & Management System (TVMS): a TMS specialised in the predictive planning of your rail and intermodal transport by integrating real-time visibility into your processes. This collaborative tool simplifies exchanges between the logistics operator, shippers, carriers and customers for a better execution of transport flows. Integrated with more than 40 rail operators and wagon rental companies, Everysens brings the whole rail and intermodal ecosystem to their industrial customers. Everysens is trusted by the largest chemical, cereals, steel and construction materials companies (among which Arkema, TotalEnergies, ArcelorMittal, HeidelbergCement, CRH) to empower their CO2 and modal shift strategies thanks to simpler rail processes.
Learn more at www.everysens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005844/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
